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Abstract. Trachoma programs use annual antibiotic mass drug administration (MDA) in evaluation units (EUs) that
generally encompass 100,000–250,000 people. After one, three, or five MDA rounds, programs undertake impact sur-
veys. Where impact survey prevalence of trachomatous inflammation—follicular (TF) in 1- to 9-year-olds is ³ 5%, ³ 1
additional MDA rounds are recommended before resurvey. Impact survey costs, and the proportion of impact surveys
returning TF prevalence ³ 5% (the failure rate or, less pejoratively, theMDAcontinuation rate), therefore influence the cost
of eliminating trachoma. We modeled, for illustrative EU sizes, the financial cost of undertaking MDA with and without
conducting impact surveys. As an example, we retrospectively assessed how conducting impact surveys affected costs
in the United Republic of Tanzania for 2017–2018. For EUs containing 100,000 people, the median (interquartile range)
cost of continuingMDAwithout doing impact surveys isUSD28,957 (17,581–36,197) per EUper year,whereascontinuing
MDA solely where indicated by impact survey results costs USD 17,564 (12,158–21,694). If the mean EU population is
100,000, then continuing MDA without impact surveys becomes advantageous in financial cost terms only when the
continuation rate exceeds 71%. For the United Republic of Tanzania in 2017–2018, doing impact surveys saved enough
money to provide MDA for > 1,000,000 people. Although trachoma impact surveys have a nontrivial cost, they generally
save money, providing EUs have > 50,000 inhabitants, the continuation rate is not excessive, and they generate reliable
data. If all EUs pass their impact surveys, then we have waited too long to do them.
INTRODUCTION
Trachoma causes blindness among the poorest people on
the planet.1 Trachomatous blindness arises from repeated
conjunctival Chlamydia trachomatis infection and the eyelid
scarring that accumulates from the associated episodes of
active (inflammatory) trachoma.2 The disease can be elimi-
nated as a public health problem through a four-pronged
strategy summarized by the acronym SAFE: surgery (S) for
individuals with advanced, blinding disease; antibiotics (A)
to clearC. trachomatis infection; and facial cleanliness (F) and
environmental improvement (E) to reduce ocular C. trachomatis
transmission.
The A, F, and E components of SAFE are delivered at the
evaluation unit (EU) level. Evaluation units are generally pop-
ulations of 100,000–250,000 people3; however, for practical
reasons (including expediency at program inception3 or the
size of local administrative divisions for healthcare manage-
ment purposes4), they are sometimes smaller4 or larger4,5 than
this. Five annual rounds of EU-wide mass drug administration
(MDA) of antibiotics active against ocular C. trachomatis6 are
undertaken wherever the prevalence of the active trachoma
sign trachomatous inflammation—follicular (TF7) in1- to9-year-
olds is ³ 30%. Three annual rounds are undertaken wherever
the TF prevalence is 10–29.9%. Where the TF prevalence is
5.0–9.9%, the WHO recommends targeted treatment3; in
recent years, this has been programmatically applied by tar-
geting all EU residents in a single roundofMDA8; the alternative
targeting approaches of offering antibiotics only to individuals,9
households,10–12 or communities13 with active trachoma hav-
ing been assessed as likely ineffective, impractical at scale, or
both. Antibiotic MDA for trachoma should always be accom-
panied by implementation of F and E; however, the evidence
base for F and E is weaker than that for A.14,15
Because decisions concerning implementation of SAFE’s A
component rest on EU-level prevalence of TF, reliable TF
prevalence data are critical. Recently, the global trachoma
program has made important investments in appropriately
scoping out16 and mapping17–21 suspected endemic pop-
ulations using standardized, quality-controlled, and quality-
assured approaches.22–24 Where baseline TF prevalence is
< 5%, the A component is not indicated for trachoma elimi-
nation purposes, but the need for interventions to improve
access to water and sanitation may be highlighted if current
access is suboptimal.25 Where baseline TF prevalence is ³
5%, A, F, and E are indicated as noted earlier, with impact
surveys due 6–12 months after the last planned round of
MDA.26 Programs use impact survey TF prevalence to de-
termine whether further MDA rounds should be planned. Im-
pact survey TF prevalence < 5% signals an end to MDA for
trachoma elimination purposes and the start of a 2-year surveil-
lance period. At the end of those 2 years, a pre-validation surveil-
lance survey is undertaken to ensure that TF prevalence has not
recrudesced to ³ 5%.26
Baseline,21 impact,27 and pre-validation surveillance28
surveys are generally all performed using population-based,
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two-stage cluster sampling.29 Survey costs are not
insignificant.30–32 Trachoma programs are currently un-
dergoing considerable expansion in an effort to achieve the
WorldHealthAssembly–endorsedgoal of global elimination of
trachoma as a public health problem.33,34 During a session of
the 2018meeting of the Coalition for Operational Research on
neglected tropical diseases (NTDs), discussion focused on
the proportion of EUs undergoing trachoma impact surveys in
a defined period returning a TF prevalence estimate above the
elimination threshold, a proportion sometimes referred to as
the failure rate. This rate was said to be higher than the anal-
ogous failure rate of lymphatic filariasis transmission assess-
ment surveys, with the implication being that money for
trachoma elimination was being inefficiently spent on surveys
conducted too soon. It led us to wonder: Is a nonzero failure
rate necessarily bad?Here, we demonstrate that the answer is
no, by modeling the financial cost of undertaking MDA with
and without conducting impact surveys. And, because in this
context failure turns out to be helpful, we will henceforth use
the more neutral term continuation rate to refer to the pro-
portion of EUs undergoing impact surveys that derive a
renewed mandate for MDA.
MATERIALS AND METHODS
To obtain an impact survey continuation rate of 0% (and
thereby save money on monitoring and evaluation by not
needing to repeat impact surveys after further roundsofMDA),
all impact surveys would need be delayed until a TF preva-
lence < 5% was thought to be virtually guaranteed. We
therefore compared the cost of using impact surveys to guide
decision-making on ongoing annual MDA with the cost of
simply continuing MDA for another year, considering only the
financial costs to the trachoma program in a single year of its
operation.
We hypothesized a set of trachoma-endemic EUs in
which, at the beginning of the program year, the recom-
mended number of annual rounds of MDA for trachoma
elimination purposes had already been completed. Assum-
ing appropriate antibiotics were available, the trachoma
program manager could—in theory—choose between two
strategies:
(a) undertake an impact survey in each EU, then decide
whether to stop or continue MDA in the EU on the basis of
the survey outcome; or
(b) undertake another round of MDA in each EU, postponing
impact surveys until the next year or beyond.




Pcontinuation  ucMDA  N

< ucMDA  N,
where Csurvey is the financial cost of an impact survey in one
EU, excluding salaries of (but including fieldwork per diems
for) survey team members; Pcontinuation is the impact survey
continuation rate; ucMDA is the unit cost ofMDAper person per
year excluding the cost of antibiotics and excluding salaries
and per diems of distribution team members; and N is the
mean EU population.















that is, when the probability of continuation is less than 1 mi-
nus the ratio of the impact survey cost to the cost of one round
of MDA.
We know that ucMDA (not just the total cost ofMDA) depends
onN.35 The elasticity of ucMDA with respect to population size is
about −0.5, meaning that for a 10% increase in N, ucMDA de-
creases by amean of 5%.We therefore used a published web-
based application (https://healthy.shinyapps.io/benchmark/35)
to generate estimates of ucMDA for our analyses. This applica-
tion requires several parameters to be specified; we assumed
an MDA coverage rate of 85%would be achieved in the fourth
year of a subnational, annual campaign distributing only anti-
biotics for trachoma, in a country other than a small-island
developing state, using unpaid volunteers to distribute in the
community (rather than in schools). Per-capita gross domestic
product (GDP) andpopulationdensitywere set at $936and123
people per km2, respectively: real-world data from the United
Republic of Tanzania in 2017. These choices were consistent
with the scenario under consideration: WHO recommends that
programs achieve at least 80% coverage when undertaking
antibioticMDA3;wherebaselineTFprevalence is 10–29.9%, an
impact survey to determine whether or not MDA should con-
tinuewouldnormally beundertakenbefore the fourth round, the
UnitedRepublic of Tanzania is trachomaendemic,36 and so on.
The derived ucMDA estimates were $0.13 (2015 USD; 95% CI:
0.08–0.17), $0.18 (0.11–0.23), $0.20 (0.12–0.26), $0.23
(0.14–0.29), $0.28 (0.17–0.35), and 0.39 (0.24–0.49) for EUs of
500,000, 250,000, 200,000, 150,000, 100,000, and 50,000
people, respectively.
Csurvey can also depend on N. The standard error of a
prevalence estimate decreases as the sampling fraction in-
creases, allowing smaller sample sizes (for the same level
of precision) with smaller underlying populations. In practice,
sample sizes do not vary much across the WHO-
recommended EU population range: a decrease in EU pop-
ulation size from 250,000 to 100,000 decreases the estimated
sample size requirement for 1- to 9-year-olds by only
2.3–3.2%, depending on the other parameters used in the
calculation.29 What if EUs are constructed to be even smaller
than 100,000 people? Although the number of children that
should be examined to maintain acceptable precision de-
creasesmore steeply, the requirement for those children to be
chosen fromat least 20 clusters29means thatCsurvey tends not
to fall far. Program data suggest variation in impact survey
costs is driven primarily by context-specific expenditure on
per diems and transport, with minor economies of scale seen
when larger numbers of surveys are undertaken in a single
round.32 To parameterize Csurvey for the current analyses, we
used published data compiled from 322 trachoma impact and
surveillance surveys conducted in 11 countries; the median
per-EU financial cost (in 2017 USD) was $8,298 (interquartile
range [IQR]: $6,532–$10,111).32 (Surveillance surveys use
the same systems and methods and have the same sample
size requirements as impact surveys, and the costs of
these two survey types do not differ significantly from
each other [Mann–Whitney P = 0.68; 95% CI for cost
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difference−$620–$788].32 It is therefore appropriate touse the
median cost for both survey types combined as the Csurvey
value in the present analyses.)
Our choices of, for example, per-capitaGDPandpopulation
density when deriving ucMDA estimates from https://
healthy.shinyapps.io/benchmark/ were necessarily arbitrary
and made simply to parameterize the model. We therefore
performed a separate analysis using the median ucMDA de-
termined from150 observations in 29 studies identifiedas part
of a published systematic review: $0.20 (2015 USD).35 We
converteducMDA estimates from2015USD to2017USDusing
an inflation factor of ×1.0342.
We obtained empirical data on Pcontinuation by compiling
global impact survey continuation rates using all surveys
completed using Tropical Data (www.tropicaldata.org) in the
calendar years 2017 and 2018. We used these inputs, and the
same median and IQR Csurvey as earlier,
32 to determine the
global per-EU cost of strategies (a) and (b) and the Pcontinuation
at which the costs would equalize, for the same six illustra-
tive Ns.
As a case example, we compared the cost of implement-
ing each strategywithin the trachomaelimination programof
the United Republic of Tanzania for 2017 and 2018. For this
analysis, we used survey and cost data collected retro-
spectively from the actual surveys implemented during that
period.
RESULTS
From January 1, 2017 to December 31, 2018, Tropical Data
supported trachoma programs to complete 538 impact sur-
veys in 25 countries, representing 92% of all impact surveys
completed for trachoma globally during that 2-year period.
A total of 170 (32%) of those 538 impact surveys returned
estimates of TF prevalence in 1- to 9-year-olds of ³ 5%, in-
dicating MDA continuation. Continuation rates ranged by
country from 0% to 100% of EUs. Fourteen of 25 countries
had nonzero continuation rates.
For EUs containing a mean of 100,000 people, the median
cost of continuing MDA without doing impact surveys would
be USD 28,957 per EU per year, whereas the median cost
of doing impact surveys and continuing MDA only where
indicated by TF prevalence would be USD 17,564 (Table 1).
ContinuingMDAwithout impact surveys becomes advantageous
(in financial cost terms) only when the continuation rate ex-
ceeds 71%.
In the United Republic of Tanzania in the 2 years from
January 1, 2017 to December 31, 2018, 20 impact surveys
were required. The continuation ratewas 6/20 (30%). The cost
of not doing impact surveys and just undertakingMDA in each
of those 20 EUs (strategy [b]) would have been $409,721. The
cost of the process actually performed—undertaking impact
surveys and implementing MDA only where indicated (strat-
egy [a])—was $307,790, a saving of $101,931 (25%, Table 2).
Based on the local cost of MDA in 2017–2018 ($0.0981 per
person, Table 2), this is equivalent to the cost of undertaking
MDA for more than one million people.
DISCUSSION
A trachoma elimination program in which all impact surveys
estimate TF to be <5%haswaited too long to do themandwill
in the meantime have incurred unnecessary intervention
costs.Doing surveys todeterminewhetherMDA is still needed
is generally cheaper than just continuingMDA. The qualification
generally is needed in that statement because the certainty of
the conclusion would diminish when survey costs or survey
continuation rates rise, when MDA costs fall, or for mean EU
populations less than 50,000. This observation underlines the
merit of the 2010 WHO recommendation that trachoma pro-
gram EUs be framed as populations of 100,000–250,000 peo-
ple,3 a recommendation that tried to balance considerations
relating to disease control, ethics, existing administrative divi-
sions, local politics, andprogramcosts. Thecost element in that
balance was intuitive; the present analyses allow the intuition
to be formally tested—and found to be correct. Although it
may not be straightforward for health ministries to combine
local administrative areas with small populations into a single
EU for trachoma elimination purposes, where local adminis-
trative areas have very small populations, doing so probably
increases the cost efficiency of the elimination program.
Understanding that impact surveys savemoney even when
someEUs fail them is important. Thecorollary—that a nonzero
continuation rate should be welcomed—is even more impor-
tant because it can seemcounterintuitive. Spendingmoneyon
monitoring and evaluation can make program managers and
partners uncomfortable. The proportion of funds that can be
spent on monitoring and evaluation is capped in some
TABLE 1
Cost per trachoma-endemic EU in a single programmatic year for (a) undertaking an impact survey in each EU, and then making a decision on
whether to stop or continue annual antibiotic MDA for trachoma elimination purposes in that EU on the basis of the outcome; and (b) simply
continuing MDA without first conducting impact surveys, and the continuation rate at which financial costs for the two strategies equalize, for
different mean EU populations ðNÞ
N
Cost per EU of impact surveys then MDA where
indicated*, 2017 USD†
Cost per EU of continuingMDAwithout first conducting
impact surveys‡, 2017 USD†,
Impact survey continuation rate at which financial costs
equalize, %†
50,000 14,751 (10,503–18,219) 20,166 (12,410–25,337) 58 (47–60)
100,000 17,564 (12,158–21,694) 28,957 (17,581–36,197) 71 (62–72)
150,000 19,715 (13,482–24,507) 35,679 (21,718–44,987) 76 (69–77)
200,000 21,536 (14,474–27,320) 41,368 (24,820–53,778) 79 (73–81)
250,000 23,190 (15,633–29,140) 46,539 (28,440–59,466) 82 (77–82)
500,000 29,809 (19,770–38,241) 67,223 (41,368–87,907) 87 (84–88)
EU = evaluation unit; IQR = interquartile range; MDA = mass drug administration. Calculations were based on the global median (and IQR of) impact survey costs from Stelmach et al.,32 the
2017–2018 global Tropical Data impact survey continuation rate of 32%, and the globalmedian (and 95%CIs of) per-person financial cost ofMDA fromFitzpatrick et al.,35 inflated from2015USD to
2017 USD using a factor of ×1.0342.
* Referred to in the text as “strategy (a).”
†First figure in each cell uses the median survey and MDA costs; figures in parentheses reflect the IQR of survey costs and 95% CI of MDA costs.
‡Referred to in the text as “strategy (b).”
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program grants, and the view is sometimes expressed that
funds allocated to these activities would bemore productively
used for disease control. This ignores the fact that programs
must periodically reconfirm the presence of the disease being
controlled. We have shown in this article that, assuming EUs
are larger than50,000, and thecontinuation rate andunit costs
are not too dissimilar from those included in our models,
surveys savemoney for the program even in the year that they
are performed. The reason for the saving is that MDA is de-
livered only to people who actually need it.
We note that survey data quality is paramount.23 Mis-
classifying EUs by conducting surveys with inadequate
sample sizes, inappropriate sampling strategies, un-
standardized graders, or inappropriate analysis methods in-
validates any consideration of the use of surveys to improve
cost efficiency.Wenote also that specific local conditionsmay
fall outside the range of our illustrative calculations. The for-
mulas and code (provided here: https://github.com/mathi-eu/
tis-failure) will allow replication or contextual adjustment.
Our analyses are relatively simple. They have several in-
herent limitations: the first ofwhich is that they include only the
financial costs to the program. We ignored the economic
costs of the time of survey field-workers, time of survey par-
ticipants, time of antibiotic distribution staff, and time of an-
tibiotic recipients. Second, the ucMDA estimates that we used
may be imperfect. They were derived from studies across
multiple NTDs35 because this allowed us to adjust for the
elasticity of ucMDA with changing EU population size. Our
ucMDA estimates also excluded per diems of MDA teams; by
contrast, we included the cost of per diemsof survey fieldwork
teams in our Csurvey. Actual published ucMDA estimates for
trachoma elimination programs range from $0.25 (Mali; year
2000–2002) to $1.37 (South Sudan; 2010).37–39 Undertaking a
preparatory population census or return household visits to
maximize population coverage makes ucMDA more expen-
sive.37 Third, for the sake of simplicity and robustness, we
ignored the finite population correction factor that canbeused
to reduce survey sample sizes for EUs with smaller pop-
ulations29; this would have reduced our Csurvey. Fourth, again
for the sake of simplicity, we limited our analyses to costs in
the program year in which impact surveys are due. This dis-
regarded thecost of ongoing annualMDA in subsequent years
when the likelihood of it being necessary for trachoma elimi-
nation purposes would continue to wane. Fifth and perhaps
most critically, we ignored externalities that would need to be
accounted for were annual antibiotic MDA to continue in-
definitely without regular affirmation of need. These external-
ities include a perceived lack of progress toward public health
goals, with resulting loss of stakeholder confidence40; eco-
nomic and environmental costs of manufacture and shipment
of antibiotics; and possible emergence of antimicrobial
resistance.41,42 Each of these five limitations is inherently
conservative: had we incorporated the relevant consider-
ations in our model, the case for doing more impact surveys
rather than fewerwould havebeenevenmore compelling. This
article, then, presents the short-term financial rationale for
undertaking high-quality impact surveys at the timewhen they
are due.
The potential externalities of completely interrupting
transmission of ocular C. trachomatis,43–45 reducing
transmission of genital C. trachomatis,46 improving child
survival,47,48 or eradicating yaws49–51 might, of course,
strengthen the argument for continuing MDA. (Evidence for
each of these possible outcomes of MDA is incomplete.)
TABLE 2
Retrospective estimate of costs to the United Republic of Tanzania’s trachoma elimination program of either (a) undertaking an impact survey in
each EU in which one was due in 2017 or 2018 and then deciding whether to stop or continue annual antibiotic MDA for trachoma elimination

































Nkasi Nkasi 2018 8,719.32 318,958 28,884.11 < 5% (no) 8,719.32 28,884.11 20,164.79
Kalambo Kalambo 2018 7,610.23 235,589 21,351.88 5–9.9% (yes) 28,962.11 21,351.88 −7,610.23
Ngara Ngara 2018 9,501.14 386,638 16,728.38 < 5% (no) 9,501.14 16,728.38 7,227.24
Songwe Songwe 2018 6,546.59 153,820 10,947.88 5–9.9% (yes) 17,494.47 10,947.88 −6,546.59
Chunya Chunya 2018 8,673.86 163,315 12,595.67 < 5% (no) 8,673.86 12,595.67 3,921.80
Bahi Bahi 2018 6,382.95 251,080 22,565.15 < 5% (no) 6,382.95 22,565.15 16,182.20
Chemba Chemba 2018 8,401.14 267,014 32,301.05 5–9.9% (yes) 40,702.19 32,301.05 −8,401.14
Liwale Liwale 2018 7,610.23 96,427 18,195.65 < 5% (no) 7,610.23 18,195.65 10,585.42
Longido Longido 2018 10,616.59 144,410 18,468.33 5–9.9% (yes) 29,084.92 18,468.33 −10,616.59
Monduli Monduli 2018 10,616.59 186,477 20,565.78 < 5% (no) 10,616.59 20,565.78 9,949.20
Ngorongoro Ngorongoro 2018 11,611.66 204,487 24,463.96 10–29.9% (yes) 36,075.61 24,463.96 −11,611.66
Kalambo Kalambo 2017 10,341.64 235,589 26,436.67 5–9.9% (yes) 36,778.31 26,436.67 −10,341.64
Kilindi Kilindi 2017 8,788.41 258,372 26,248.10 < 5% (no) 8,788.41 26,248.10 17,459.69
Itigi Itigi 2017 8,427.59 127,680 14,067.43 < 5% (no) 8,427.59 14,067.43 5,639.83
Manyoni Manyoni 2017 8,597.45 213,010 20,933.81 < 5% (no) 8,597.45 20,933.81 12,336.36
Kongwa* Kongwa south 2017 6,973.86 197,409 23,779.53 < 5% (no) 6,973.86 23,779.53 7,970.53
Kongwa* Kongwa north 2017 8,835.14 113,042 < 5% (no) 8,835.14
Chamwino* Chamwino south 2017 8,256.36 155,647 39,564.67 < 5% (no) 8,256.36 39,564.67 22,820.48
Chamwino* Chamwino north 2017 8,487.73 147,574 < 5% (no) 8,487.73
Meatu Meatu 2017 8,821.82 321,781 31,622.54 < 5% (no) 8,821.82 31,622.54 22,800.72
Totals 173,820.28 4,179,319 409,720.59 – 307,709.06 409,720.59 101,930.53
EU = evaluation unit; MDA = mass drug administration.
* Districts divided into two EUs for impact survey purposes.
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Similarly, if early discontinuation of MDA was strongly as-
sociated with later recrudescence of active trachoma, then
both the benefit of continuing MDA for longer and the
eventual financial cost of not doing so would be likely to
increase. We also disregard the externalities involved in
undertaking integrated surveys52 and integrated disease
control and elimination programs,53 which might signifi-
cantly affect the economic equation.
An additional limitation of this study comes in consid-
ering how to apply its conclusions. Programs that have
conducted impact surveys for only a few EUs will have
continuation rates that are liable to change profoundly as
more local experience accrues. And perhaps more im-
portantly, use of a high continuation rate as the lonemetric
to justify omitting impact surveys would be to ignore the
important nonfinancial considerations outlined earlier.
It is worth noting that the counterfactual scenario that we
presented—of simply continuing MDA for trachoma until im-
pact survey failure becomes extremely unlikely—would be
difficult to put into practice, for two reasons. First, to make
donated drug available, the International Trachoma Initiative
(which serves as the steward for Pfizer’s [New York, NY]
Zithromax® donation) requires program managers to provide
evidence of ongoing need for MDA in the form of high-quality
TF prevalence data.8 Without the donation, continuation of
MDA would require azithromycin to be purchased, increasing
ucMDA. Second, we do not yet know enough to be able to
confidently predict the number of annual rounds of MDA re-
quired to reduce the TF prevalence in any particular EU to <
5%. Many variables, including parameters related to water,
sanitation, eye-seeking flies, facial cleanliness, and pop-
ulation density,2 are associated with TF prevalence and could
conceivablymodify the effect of antibiotic treatment; the F and
E components of SAFE attempt to influence some of these
parameters in parallel with antibiotic treatment,54 but have
unknown effectiveness. The influence of EU-level antibiotic
coverage (let alone heterogeneity of coverage spatially or by
age and gender) is unclear.55,56 Given increasing concern
about global antimicrobial resistance and the need topreserve
theutility ofmacrolides,57 taking steps toensure that antibiotic
MDA occurs only where and when justified is critical, partic-
ularly if it also allows scarceglobal health dollars to bedirected
to other areas of need.
Although our analysis was driven by trachoma program
data, similar considerations apply to other disease elimi-
nation efforts in which mass interventions are undertaken.
Other NTD programs provide an immediate parallel.58 As a
touchstone for the 2030 Agenda for Sustainable Devel-
opment, themovement to control, eliminate, and eradicate
NTDs has few equals, such is the impact of the diseases on
the impoverished populations in which they thrive.59 Good
data are critical for all.60 We hope that this article will en-
courage ongoing support for both interventions against
these diseases and the high-quality monitoring and eval-
uation needed to guide implementation.
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